Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Vera Therapeutics is a late clinical-stage biotechnology company focused on developing transformative treatments for serious immunologic diseases [3] Company Overview - Vera Therapeutics' mission is to advance treatments that target the source of disease to change the standard of care for patients [3] - The lead product candidate is atacicept, a fusion protein administered at home as a subcutaneous weekly injection, which blocks B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL) [3] - Atacicept is aimed at treating autoimmune diseases such as immunoglobulin A nephropathy (IgAN) and lupus nephritis, with ongoing evaluations for additional diseases [3] - The company holds an exclusive license agreement with Stanford University for a next-generation fusion protein, VT-109, targeting BAFF and APRIL, with potential across B-cell-mediated diseases [3] - Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize BK virus infections, particularly in kidney transplant recipients [3] - The company retains all global developmental and commercial rights to atacicept, VT-109, and MAU868 [3] Event Participation - The management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, and will participate in one-on-one investor meetings [1] - The presentation is scheduled for January 13, 2026, at 2:15 PM PST, with a webcast available [2]